Table 1.
Demographic and Clinical Characteristics of Patients With DLBCL Enrolled Onto the BMT CTN 0401 Trial
| Characteristic | B-BEAM (n = 111) |
R-BEAM (n = 113) |
||
|---|---|---|---|---|
| No. of Patients | % | No. of Patients | % | |
| Received transplantation | 104 | 108 | ||
| Eligible for study | 103 | 107 | ||
| Male | 68 | 61.3 | 74 | 65.5 |
| Age, years | ||||
| Median | 56.8 | 58.5 | ||
| Range | 19.8-74.9 | 24.0-76.6 | ||
| Race, white | 99 | 89.2 | 103 | 91.2 |
| KPS | ||||
| 100 | 29 | 26.1 | 26 | 23 |
| 90 | 67 | 60.4 | 63 | 55.8 |
| 80 | 12 | 10.8 | 19 | 16.8 |
| 70 | 3 | 2.7 | 5 | 4.4 |
| Disease status at transplantation | ||||
| PR1 | 21 | 18.9 | 15 | 13.3 |
| REL1 | 35 | 31.5 | 45 | 39.8 |
| CR2 | 55 | 49.5 | 53 | 46.9 |
| No. of prior therapies | ||||
| 1 | 2 | 1.8 | 7 | 6.2 |
| 2 | 93 | 83.8 | 83 | 73.5 |
| 3 | 16 | 14.4 | 23 | 20.4 |
Abbreviations: B-BEAM, iodine-131 tositumomab plus carmustine, etoposide, cytarabine, and melphalan; BMT CTN, Blood and Marrow Transplant Clinical Trials Network; CR2, second complete remission; DLBCL, diffuse large B-cell lymphoma; KPS, Karnofsky performance score; PR1, first partial response; R-BEAM, rituximab plus carmustine, etoposide, cytarabine, and melphalan; REL1, first relapse (chemotherapy sensitive).